Patents by Inventor Birgit Bramlage

Birgit Bramlage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting expression of the PCSK9 gene
    Patent number: 8809292
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: August 19, 2014
    Assignee: Alnylam Pharmaceuticals, Inc
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Compositions And Methods For Inhibiting Expression Of The PCSK9 Gene
    Publication number: 20130331430
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene.
    Type: Application
    Filed: May 15, 2012
    Publication date: December 12, 2013
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Compositions and Methods for Inhibiting Expression of a Gene from the JC Virus
    Publication number: 20130158102
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC Virus. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC Virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC Virus in a cell.
    Type: Application
    Filed: February 27, 2013
    Publication date: June 20, 2013
    Inventors: Pamela Tan, Dinah Sah, Birgit Bramlage
  • Compositions and methods for inhibiting expression of a gene from the JC virus
    Patent number: 8410261
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC Virus. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC Virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC Virus in a cell.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: April 2, 2013
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Pamela Tan, Dinah Sah, Birgit Bramlage
  • Compositions and methods for inhibiting expression of huntingtin gene
    Patent number: 8314075
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: November 20, 2012
    Assignee: Alynylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES
    Publication number: 20120282280
    Abstract: This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical 5 compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: June 30, 2010
    Publication date: November 8, 2012
    Inventors: Birgit Bramlage, Ulrich Brinkmann, Rebecca Croasdale, Simone Dill, Wilma Dormeyer, Guy Georges, Michael Grote, Alexander Haas, Eike Hoffman, Ludger Markus Ickenstein, Kerstin Jahn-Hofman, Matthias John, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
  • Compositions and methods for inhibiting expression of the PCSK9 gene
    Patent number: 8222222
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by PCSK9 gene expression and the expression of the PCSK9 gene using the pharmaceutical composition; and methods for inhibiting expression of a PCSK9 gene in a cell.
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: July 17, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Compositions and Methods for Inhibiting Expression of RRM2 Genes
    Publication number: 20120159657
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.
    Type: Application
    Filed: October 18, 2011
    Publication date: June 21, 2012
    Inventors: John Frederick Boylan, Birgit Bramlage, Markus Hossbach, John Reidhaar-Olson
  • RNAi Modulation of AHA and Therapeutic Uses Thereof
    Publication number: 20120142757
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.
    Type: Application
    Filed: January 4, 2012
    Publication date: June 7, 2012
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Rainer Constien, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, William Balch
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUNTINGTIN GENE
    Publication number: 20120095076
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Application
    Filed: October 4, 2011
    Publication date: April 19, 2012
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • Compositions and methods for inhibiting expression of the MYC gene
    Patent number: 8124752
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the MYC gene (MYC gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the MYC gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by MYC gene expression and the expression of the MYC gene using the pharmaceutical composition.
    Type: Grant
    Filed: July 9, 2007
    Date of Patent: February 28, 2012
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: David Bumcrot, Birgit Bramlage, Pamela Tan
  • RNAi modulation of Aha and therapeutic uses thereof
    Patent number: 8114984
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: February 14, 2012
    Assignees: Alnylam Pharmaceuticals, Inc., The Scripps Research Institute
    Inventors: Rainer Constien, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, William Balch
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A GENE FROM THE JC VIRUS
    Publication number: 20120022141
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC Virus. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC Virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC Virus in a cell.
    Type: Application
    Filed: October 4, 2011
    Publication date: January 26, 2012
    Inventors: Pamela Tan, Dinah Sah, Birgit Bramlage
  • Compositions and methods for inhibiting expression of Huntingtin gene
    Patent number: 8080532
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: December 20, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • Compositions and methods for inhibiting expression of a gene from the JC virus
    Patent number: 8058257
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC Virus. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC Virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC Virus in a cell.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: November 15, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Pamela Tan, Dinah Sah, Birgit Bramlage
  • dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION
    Publication number: 20110230546
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.
    Type: Application
    Filed: May 26, 2011
    Publication date: September 22, 2011
    Inventors: John Benson, Birgit Bramlage, Kevin Fitzgerald, Pamela Tan, Hans-Peter Vornlocher
  • Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
    Publication number: 20110230542
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene.
    Type: Application
    Filed: September 4, 2009
    Publication date: September 22, 2011
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • dsRNA compositions and methods for treating HPV infection
    Patent number: 7956177
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: June 7, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: John Benson, Birgit Bramlage, Kevin Fitzgerald, Pamela Tan, Hans-Peter Vornlocher
  • Compositions and Methods for Inhibiting Expression of TGF-BETA Receptor Genes
    Publication number: 20110119781
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a TGF-beta receptor type I gene, comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length and which is substantially complementary to at least a part of a TGF-beta receptor type I gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a TGF-beta receptor type I gene using said pharmaceutical composition; and methods for inhibiting the expression of a TGF-beta receptor type I gene in a cell.
    Type: Application
    Filed: July 8, 2009
    Publication date: May 19, 2011
    Inventors: Birgit Bramlage, Markus Hossbach, Pamela Tan, Hans-Peter Vamlocher
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF KIF10 GENES
    Publication number: 20110112176
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a KIF10 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a KIF10 gene using said pharmaceutical composition; and methods for inhibiting the expression of KIF10 in a cell.
    Type: Application
    Filed: November 5, 2010
    Publication date: May 12, 2011
    Inventors: John Frederick Boylan, Birgit Bramlage, Wei He, Markus Hossbach, Ingo Roehl